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In continuation of our search for new bioactive compounds from soil microbes, a
fluorescent Pseudomonas strain isolated from paddy field soil of Kuttanad, Kerala,
India was screened for the production of bioactive secondary metabolites. This strain
was identified as Pseudomonas mosselii through 16S rDNA gene sequencing followed
by BLAST analysis and the bioactive metabolites produced were purified by column
chromatography (silica gel) and a pure bioactive secondary metabolite was isolated.
This bioactive compound was identified as Pseudopyronine B by NMR and HR-ESI-MS.
Pseudopyronine B recorded significant antimicrobial activity especially against Gram-
positive bacteria and agriculturally important fungi. MTT assay was used for finding
cell proliferation inhibition, and Pseudopyronine B recorded significant antitumor activity
against non-small cell lung cancer cell (A549), and mouse melanoma cell (B16F10). The
preliminary MTT assay results revealed that Pseudopyronine B recorded both dose-
and time-dependent inhibition of the growth of test cancer cell lines. Pseudopyronine B
induced apoptotic cell death in cancer cells as evidenced by Acridine orange/ethidium
bromide and Hoechst staining, and this was further confirmed by flow cytometry
analysis using Annexin V. Cell cycle analysis also supports apoptosis by inducing
G2/M accumulation in both A549 and B16F10 cells. Pseudopyronine B treated cells
recorded significant up-regulation of caspase 3 activity. Moreover, this compound
recorded immunomodulatory activity by enhancing the proliferation of lymphocytes.
The production of Pseudopyronine B by P. mosselii and its anticancer activity in
A549 and B16F10 cell lines is reported here for the first time. The present study has
a substantial influence on the information of Pseudopyronine B from P. mosselii as
potential sources of novel drug molecule for the pharmaceutical companies, especially
as potent antimicrobial and anticancer agent.
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INTRODUCTION
The discovery of antibiotics has decreased the spread and
severity of a broad range of infectious diseases caused by
human pathogenic microbes. However, due to the wide
spread use of antibiotics, the competence of many introduced
antibiotics in the market is being threatened by the rise of
microbial pathogens which are resistance to the current clinical
chemotherapeutic agents (Cowan, 1999). Human infections
owing to multi-drug-resistant microbes is a serious challenge
to many patients, especially those, are in hospitals (Arias
and Murray, 2009; Fischbach and Walsh, 2009). Infectious
diseases account for more than 13 billion human deaths
worldwide, which accounts for about 25% of all deaths (Zin
et al., 2011). The antibiotic treatments of various infectious
diseases are also getting limited due to the reemergence of
multi-drug-resistance (MDR) pathogenic microbes, which
have been frequently reported from many parts of the world.
Methicillin-resistant Staphylococcus aureus (MRSA) is one of
the important drug resistant pathogen, which is frequently
reported by many clinicians worldwide. A part from MRSA
and VRSA (vancomycin resistant S. aureus), several other drug
resistant and pan-drug-resistant (PDR) microbes especially
Gram-negative bacteria, including carbapenem resistant
Pseudomonas aeruginosa, Enterococcus faecium, Klebsiella
pneumoniae, Acinetobacter baumannii, Enterobacter sp., and
Stenotrophomonas maltophilia, are emerging as an important
health problem to human being (Huang et al., 2013). Recently,
few novel drugs have been industrialized exactly for treating
various Gram-negative MDR/PDR bacteria (Payne et al.,
2006; Vaara et al., 2010; Velkov et al., 2010). Many bioactive
compounds from natural sources have played an important role
in the discovery of many antibiotics which are used clinically.
Moreover, 70% of the clinically used antimicrobials are either
unchanged natural compounds used directly or derived from
natural compounds by synthetic tailoring (Singh et al., 2011).
Thus, more investigation should be initiated for discovering and
developing novel antimicrobial molecules especially from natural
sources is urgently needed.
At present, one in four deaths in the USA is because of
various tumors (Fadeyi et al., 2013). When classified within
age groups, the tumor is one of the five important reasons of
death among humans (males and females) and the single major
cause of human death around the world (Fadeyi et al., 2013).
By 2016, cancer morbidity may increase more than 10 million
worldwide. This growing tendency also indicates a shortage in the
various current tumor treatments including surgical operation,
chemotherapy, and radiotherapy. Since the normal endurance
rates of cancer have remained essentially unaffected in spite of
such above mentioned hostile treatments, so there is an urgent
requirement for new anticancer drugs with advanced efficiency,
and fewer side effects that can be developed at a reasonable price
to common people worldwide.
Tawiah et al. (2012) reported that “Throughout the various
years, natural compounds are the most constantly fruitful basis
of diverge bioactive metabolites having several applications
in the field of modern human medicine, pharmaceutics and
agriculture.” Therefore, the search for new antimicrobials from
natural sources is an important area of many researchers
worldwide. Microorganisms from soils play an important source
of many novel antibiotic compounds due to their high abundance
and amazing diversity. There are many reports of the production
of antimicrobial metabolites by Pseudomonas spp. Some of these
antimicrobials have been chemically characterized, and their
commercial exploitation is attempted (Zhou et al., 2012).
As mentioned earlier infectious diseases and cancer is the most
leading cause of death worldwide. Therefore, novel and potent
therapeutic agents are often required to control these diseases. To
achieve this goal, several new sources of antimicrobial/anticancer
compounds ranging from natural to synthetic are currently
being explored worldwide. Therefore in our continuous search
for new bioactive secondary metabolites from soil bacteria,
Pseudopyronine B was purified from a Pseudomonas mosselii TR
strain. The current manuscript also reported the antimicrobial
and anticancer activity of Pseudopyronine B.
MATERIALS AND METHODS
Chemicals and Media Used in Current
Study
All the chemicals and reagents used in the current study were
of the finest purity. All the chemicals used for separation
and purification of bioactive compounds were from Merck
(Mumbai, India). Silica gel (mesh size: 230–400) used for column
purification and precoated silica gel 60 plates (GF254) used for
thin layer chromatography (TLC) were purchased from Merck
(Germany). Various media used for microbiological investigation
were purchased from Hi-Media Laboratories Pvt. Ltd, Mumbai,
India. The antibiotics ciprofloxacin and amphotericin B, which
were used as standard positive control, were procured from
Sigma-Aldrich (USA). The Chemsketch Ultra (Toronto, ON,
Canada) software was used for drawing the chemical structure.
Bioactive Compound Producing
Bacterium
A fluorescent Pseudomonas, named as TR strain was isolated
from paddy field of Kuttanad region of Kerala, India was used
in the present study. Kuttanad is a unique agroclimatic zone in
India where paddy is cultivated below sea level and is blessed
with a rich microbial population which is not fully explored for
economic cultivation. The strain was identified as a fluorescent
Pseudomonas strain through classical identification methods.
Molecular Identification of TR Strain
through 16S rDNA Sequencing
Extraction of Bacterial DNA and Sequencing of the
16S Gene
A pure culture of bacteria was raised in 10 ml of Luria-Bertani
broth (LB) for 18 h to obtain OD value of approximately 0.7 at
600 nm. The bacterial culture broth (1.5 ml) was pelleted in a
microfuge tube for 2 min at 12,000 rpm. Total DNA was extracted
using standard phenol–chloroform extraction procedures
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(Sambrook et al., 2001). PCR amplification was done with
universal primers (f: 5′-GATTAGATACCCTGGTAGTCCAC-3′
and r: 5′-CCCGGGAACGTATTCACCG-3′) specific for the 16S
rDNA gene. The PCR reaction was carried out in a total volume
of 50 µl [DNA (100 ng), MgCl2 (4 Mm), PCR reaction buffer (1X,
Genei, Bangalore, India), each deoxyribonucleotide triphosphate
(2.5 mM), Taq polymerase (1.5 U, Genei, Bangalore, India) and
each primer (40 pmol)]. PCR cycle conditions were: 2 min initial
denaturation at 95◦C, followed by 36 cycles of denaturation
for 30 s at 95◦C, followed by 1 min primer annealing at 60◦C
and 1 min primer extension at 72◦C. Final primer extension
step was carried for 2 min at 72◦C. PCR amplification was
achieved on a Bio-Rad Thermal Cycler (USA). Amplicons were
analyzed in 1% (w/v) agarose gels. The gels were stained with
an aqueous solution containing ethidium bromide (0.5 mg/mL)
and visualized on a UV transilluminator. Amplicons were
purified using the QIA quick purification kit (Qiagen, Valencia,
CA, USA) and sequenced. The sequencing was performed on
an ABI PRISM 310 Genetic analyzer (Perkin-Elmer Applied
Biosystems, Foster City, CA, USA) using the universal primers
(described for PCR amplification) and the Big Dye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Applied
Biosystems). The 16S rDNA gene sequences (partial) obtained
were finally aligned using ABI Prism software (Perkin-Elmer,
Applied Biosystems) and compared to sequences retrieved from
GenBank Database and BLAST.
Phylogenetic Analysis
The phylogenetic investigation was performed using MEGA 6.0
software program (Molecular Evolutionary Genetics Analysis,
Version 6.0; Tamura et al., 2007). The phylogenetic tree
topologies were assessed by bootstrap analyses based on 1000
replicates, and final phylogenetic trees were constructed with
the neighbor-joining method as reported earlier (Saitou and
Nei, 1987). The taxonomic position of the present strain was
recognized based on 16S rDNA homology.
Fermentation and Extraction of Crude Bioactive
Secondary Metabolites
The bacterial production and solvent extraction of crude
bioactive secondary metabolites from TR strain were done
according to George et al. (2015) in King’s B media (KB). The
supernatant was collected according to the method of George
et al. (2015) and extracted with ethyl acetate trice (1:1 v/v) in a
globe shaped separating funnel (2 L) and the ethyl acetate portion
was collected, concentrated and dried in a Buchi rota evaporator
(40◦C) for further detailed investigations.
Purification of Bioactive Compound
Activated silica gel (230–400 mesh) was filled into a
600 mm × 30 mm long glass column using n-hexane solvent.
The crude secondary metabolite (0.85 g) was subjected to silica
gel column chromatography purification, with a elution profile
of 5% ethyl acetate (EtOAc), 10% EtOAc, 20% EtOAc, 40%
EtOAc in hexane (100 ml each), 50% EtOAc in hexane (150 ml),
100% EtOAc (100 ml), 5% MeOH in EtOAc (100 ml), obtained
75 fractions. The purity of the fractions was determined by TLC.
An aliquot of each collected fraction was spotted on the activated
TLC plates (silica gel 60; 10 cm × 10 cm). Ethyl acetate and
hexane (1:1) was used for developing TLC plates. Spots were
positioned by UV and further revealing the TLC plate to iodine
vapors. One fraction (tubes 35–37) was obtained as pure. This
fraction was evaporated to give a faint white residue (17 mg).
Initial bioactivity of this fraction was confirmed by testing against
Bacillus subtilis, which was used as indicator test microorganism.
Identification of the Bioactive Compound
The NMR spectra (1H NMR and 13C) of the pure compound
were documented using a Bruker DRX500 NMR spectrometer
(Bruker, Rheinstetten, Germany) at room temperature and
the chemical shifts are reported relative to the corresponding
reference solvent (methanol). HR-ESI-MS of the compound was
recorded using a Thermo Scientific Exactive Mass Spectrometer
(Thermo Fisher 110 Scientific, USA) with an electrospray
ionization mode.
Antimicrobial Activity of the Compound
Pathogenic Microbes Used in the Study
Bacterial
The following Gram-positive and negative pathogenic bacteria
are used for antibacterial study. Gram-positive pathogenic
bacteria: B. subtilis (MTCC 2756), Bacillus cereus (MTCC
430), S. aureus (MTCC 902), S. epidermis (MTCC 435),
and S. simulans (MTCC 3610); Gram-negative pathogenic
bacteria: Escherichia coli (MTCC 2622), Klebsiella pneumoniae
(MTCC 109), Proteus mirabilis (MTCC 425), Proteus vulgaris
(MTCC 1771), P. aeruginosa (MTCC 2642), Salmonella typhi
(MTCC 3216), and Vibrio cholerae (MTCC 3905).
Fungal
The fungal strains used in the present are Aspergillus flavus
(MTCC 183), A. fumigatus (MTCC 3376), A. niger (MTCC
282), A. tubingensis (MTCC 2425), Colletotrichum gloeosporioides
(MTCC 2151), Fusarium oxysporum (MTCC 284), Penicillium
expansum (MTCC 2006), Rhizoctonia solani (MTCC 4634), and
Trichophyton rubrum (MTCC 296).
All the test microbes were obtained from MTCC (Microbial
Type Culture Collection and GenBank), Council of Scientific and
Industrial Research- Institute of Microbial Technology (CSIR-
IMTECH), Chandigarh, India.
Determining the Antibacterial Activity of
Test Compound
Minimum Inhibitory Concentration (MIC) and
Minimum Bactericidal Concentration (MBC)
The MIC of the compound was determined according to broth
microdilution method as suggested by Clinical and Laboratory
Standard Institute, USA (Clinical and Laboratory Standards
Institute [CLSI], 2012a). Briefly, the concentration of the fresh
overnight culture of test bacteria was adjusted to 1× 105 CFU/ml
using a spectrophotometer. Dilutions of inocula were cultured
on a Nutrient agar (NA) medium to check the validity of the
inoculum and the absence of any contaminations. Different
solvent and water dilutions of test compound (0.5–1000 µg/ml)
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and ciprofloxacin (0.25–250 µg/ml) were placed in the wells
containing 150 µl of nutrient broth (NB), followed by the
addition of 10 µl of inoculum. After that, the ELISA plates
were incubated for 18–24 h at 37◦C. After incubation MIC
was determined by measuring the OD at 600 nm. The lowest
concentration of test compound that produced a significant
inhibition (around 90%) of the growth of the bacteria in
comparison with the positive control was identified as the MIC.
About 100 µl from the ELISA wells not displaying any
microbial growth in the MIC test were diluted serially using
0.85% saline and plated on NA plates to determine the MBC
values. The NA plates were incubated at 37◦C for 24 h. MBC
is defined as the lowest concentration of antibacterial agent that
reduces the viability of the initial bacterial inoculum by 99.99%.
Disk Diffusion Experiment of Test Compound
The antimicrobial activity of the pure compound was performed
by the disk diffusion assay against the test bacterial pathogens
as mentioned by CLSI, USA (Clinical and Laboratory Standards
Institute [CLSI], 2012b). The test bacterial strain preserved in NA
at 4◦C were sub-cultured in NB to get the working concentration
approximately containing 1 × 106 CFU/ml. The test compound
(MIC concentration) was loaded into a sterile disk (Hi-Media)
with 6 mm diameter. Then Mueller-Hinton agar (MHA) plates
were swabbed with each test bacterial pathogens and the
compound loaded disks were placed along with the control
antibiotics disk. Here, ciprofloxacin disks (5 µg/disk) were used
as the standard positive control and the plates were incubated
for 24 h at 37◦C until bacteria had developed in a confluent film.
The antimicrobial property of the test compound and antibiotic
was determined by measuring the zone of inhibition (diameter)
expressed in mm. The experiment was performed in triplicate
sets.
Determining the Antifungal Activity of
Test Compound
Minimum Inhibitory Concentration
The MIC of test compound against the fungi was done by broth
microdilution assay as per the recommendations of Clinical and
Laboratory Standard Institute, USA (Clinical and Laboratory
Standards Institute [CLSI], 2010, 2012c), with RPMI 1640
growth medium supplemented by L-glutamine, without sodium
bicarbonate (all from Sigma-Aldrich) and buffered to pH 7.0
according to the previously reported method (Aravind et al.,
2014). The lowest concentration of agents that produced a
significant inhibition (90%) of the growth of the test fungi in
comparison with the standard positive control was defined as the
MIC.
Disk Diffusion Experiment of Test Compound
The compound was screened for their antifungal activity against
test fungi by agar disk diffusion experiment as mentioned by
CLSI, USA (Clinical and Laboratory Standards Institute [CLSI],
2008, 2009). Briefly, PDA plates were inoculated (0.1 ml) with a
spore suspension in 0.85% sterile saline. The concentration of test
fungal suspension was adjusted to 1 × 105 CFU/ml using sterile
saline. The test compound (MIC concentrations) was loaded into
a 6-mm diameter sterile filter paper disks (Hi-Media, India), air
dried and then placed on the surface of the PDA plates swabbed
previously by test fungi. The plates were incubated at 35◦C for
48–72 h. After incubation, the antifungal activity was assessed
by measuring the zone of inhibition (diameter) and expressed in
millimeter (mm). The assay was performed in triplicate sets.
Anticancer Studies of the Test
Compound
Cancer Cell Lines Used in the Study: Its Source and
Maintenance and Treatments
The following three cancer cell lines were used in the present
investigation (1) Non-small cell lung cancer (A549), (2) mouse
melanoma cell (B16F10) and (3) liver cancer cell (HepG2)
lines and these cell lines were obtained from NCCS (National
Centre for Cell Science), Pune, India and maintained throughout
the study in Dulbecco’s Modified Eagle Medium (DMEM)
added with 3 mM of L-glutamine, 100 µg/ml of streptomycin,
100 IU/ml of penicillin, 10% heat inactivated (56◦C) fetal bovine
serum (FBS) and 25 mM of HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid]. The final pH was adjusted to 7.2
by bicarbonate solution at 37◦C in a CO2 incubator.
Stock solutions (3 mg/500 µl) of the test compound, made
in dimethyl sulfoxide (DMSO), were further dissolved in the
corresponding medium (DMEM) to the necessary working
concentrations. A549, B16F10 and HepG2 cell lines were seeded
into ELISA plates and incubated for 24 h at 37◦C in a CO2
incubator. After the cell adherence, six different concentrations of
test compound (0.1, 1, 5, 10, 50, and 100µg/ml) were added to the
wells containing test cancer cell lines, except to the control wells.
Control wells contain only DMEM nutrient medium and the test
cells. The cultures were incubated for various time periods (24,
48, and 72 h).
Anti-proliferative Activity
The cytotoxic effect of the test compound was determined
by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] methods as described earlier (Aravind et al., 2015).
The concentrations used in this study are 0.1, 1, 5, 10, 50, and
100 µg/ml.
Apoptosis Induction Assay Using the
Test Compound
Acridine Orange and Ethidium Bromide Staining
(AO/EB Staining)
Apoptotic morphology of cancer cells after treatment with
Pseudopyronine B was investigated by staining the cancer cells
with a combination of the fluorescent DNA-binding acridine
orange (AO) and ethidium bromide (EB) dyes to decide the viable
and non-viable cancer cells in a population. Cells were collected
and washed three times with PBS after being incubated with
IC50 concentration of Pseudopyronine B for 24, 48 and 72 h,
and were then stained with 100 µg/ml AO/EB stain (Sigma-
Aldrich) for 2 min. Then the color and structure of the cancer
cells were immediately recorded under an inverted fluorescence
microscope (Aravind et al., 2014).
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Detection of Morphological Apoptosis with Hoechst
33342 Staining
The morphological apoptosis like chromatin condensation in
the test cancer cell lines was observed by nuclear staining dye
Hoechst 33342 (Aravind et al., 2014). After treatment with
Pseudopyronine B (IC50 concentration) for 24, 48 and 72 h, the
A549 and B16F10 cells were washed with PBS trice and then
further fixed with methanol: acetic acid (3:1) for 10 min at room
temperature in the dark. Fixed cells were again washed with PBS
and stained with 1 µg/ml of Hoechst 33342 stain (10 mg/ml) for
10 min in the dark at room temperature. Changes in the nuclei
of cells after staining with Hoechst 33342 were recorded using
an inverted fluorescence microscope (stimulation at 350 nm and
emission at 460 nm; Leica, Germany).
Annexin V/Propidium Iodide Assay
The annexin V/propidium iodide (PI) method was done
according to the recommendation given by manufacturer’s
(Invitrogen, USA). Briefly, A549 and B16F10 cell lines were
seeded into six well plates and incubated for 24, 48, and 72 h
with Pseudopyronine B (IC50 concentration). After incubation,
the cells were collected and washed with ice-cold PBS and
centrifuged. The pellet was resuspended in 100 µl of binding
buffer containing 2.5 µl FITC conjugated Annexin V and
1 µl 100 µl/ml PI and incubated for further 15 min at room
temperature in the dark. A total of at least 10000 events were
composed and examined by BD flow cytometry (BD Biosciences,
San Jose, CA, USA; Liu et al., 2013).
Cell Cycle Analysis of Cancer Cells after Treatment
with Test Compound
The cellular DNA content and distribution in the cell cycle were
enumerated by BD flow cytometry using PI staining. A549 and
B16F10 cells were seeded in the T25 culture flask and treated
with Pseudopyronine B (IC50 concentration) for the various time
periods (24, 48, and 72 h). Cells were collected, washed with PBS
twice, and fixed in 70% ethanol at−20◦C. After fixation, the cells
were washed in PBS and centrifuged. The pellets thus obtained
was treated with RNase (1 mg/ml; Roche, Mannheim, Germany)
at 37◦C for 30 min and then incubated with PI for at least 30 min.
Cell-cycle analysis was recorded with the FACS Calibur Flow
Cytometer (BD Biosciences, San Jose, CA, USA) and the data
were analyzed with Flowjo software.
Determination of Activation of Caspase 3
Caspase-Glo assay kits (Promega) were used to determine the
activation of Caspase 3 by following manufacturer’s instructions.
A549 and B16F10 cells were plated into ELISA plates and
incubated for 24 h. After 24 h seeding, cells were treated with
test compound (5, 10, and 50 µg/ml) and incubated for 48 h.
Subsequently, 100 ml of caspase-3 assay reagent was added to
each well. After adding the reagent, the plate was incubated for
1 h in the dark and the luminescence was quantified with the
help of a microplate reader (SpectraMax M5, Molecular Devices).
The activity of Caspase was expressed as a percentage (%) of
the untreated control treatment (DMSO). The experiment was
performed in triplicate (Wang et al., 2014).
Proliferation Assay of Normal Lymphocytes
The proliferation of normal lymphocytes when treated with test
compound was done as described earlier (Aravind et al., 2014).
Statistical Analysis
Disk diffusion data was presented as mean± standard deviation.
The error bars represent ± SD. taken from three independent
experiments. Statistical analysis was performed with SPSS
(Version 17.0; SPSS, Inc., Chicago, IL, USA). The significance
level was set at P < 0.05.
RESULTS
Based on 16S rDNA Sequencing and
Phylogenetic Analysis, Bacteria Was
Identified as P. mosselii
Molecular characterization of the TR bacterium (P. mosselii) was
performed by 16S rDNA gene sequencing. PCR amplification
of 16S rDNA gene yielded -1500 bp amplicon. BLAST analysis
recorded 99% similarity to P. mosselii 16S rDNA sequence
accessible in the NCBI GenBank database and based on this our
TR strain was identified as P. mosselii. The partial 16S rDNA
gene sequence data have been deposited in the NCBI GenBank
nucleotide database under the accession number KF712283.
The phylogenetic tree clearly portrayed the relationships our
P. mosselii with other Pseudomonas strains used for the present
analysis. The present TR bacterial isolate (P. mosselii strain) was
very successfully clustered along with other P. mosselii sequences
obtained from the NCBI GenBank database further confirming
the authenticity of our isolate (Figure 1). The P. mosselii was
currently deposited in CSIR-IMTECH (Institute of Microbial
Technology, Chandigarh, India).
The Bioactive Compound Was Identified
as Pseudopyronine B Based on Detailed
Spectral Analyses
Ethyl acetate fraction of P. mosselii yielded one main compound,
which having an Rf value 0.68. Initial bioactivity of this
compound was confirmed by testing the antimicrobial activity
against B. subtilis and the compound recorded significant activity
(data not shown). The compound was identified based on the
spectral data as Pseudopyronine B (Figure 2).
Pseudopyronine B:1H NMR (500 MHz, CD3OD) δ 0.91 (2× t,
J = 6.8 Hz, 2 × 3 H), 1.27–1.39 (m, 14 H), 1.42–1.50 (m, 2 H),
1.66 (quin, J = 7.3 Hz, 2 H), 2.38 (t, J = 7.5 Hz, 2 H), 2.48
(t, J = 7.5 Hz, 2 H), 5.99 (s, 1 H); 13C NMR (126 MHz, CD3OD)
δ 12.9, 13.0, 22.2, 22.3, 22.4, 26.5, 27.5, 28.5, 28.6, 28.8, 29.2,
31.4, 31.5, 32.9, 99.6, 102.5, 163.7, 166.4, 167.4; ESI-MS [M+H]+
C18H31O3 calc′d for m/z 295.22732, found 295.22729.
Antibacterial Activity of Pseudopyronine B
The Pseudopyronine B was tested for checking its antibacterial
(MIC and MBC) activity against 13 bacterial species using
standard CLSI protocol and the values are presented in Table 1.
Pseudopyronine B recorded significant antibacterial activity
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FIGURE 1 | Phylogenic tree displaying the relationships of Pseudomonas mosselii TR strain and other known Pseudomonas species based on 16S
rDNA gene sequences (Neighbor-joining Method).
against Gram positive bacteria, while most of the tested Gram
negative bacteria recorded no activity. The microorganism that
presented highest sensitivity toward Pseudopyronine B was
S. epidermis (1 µg/ml), followed by S. aureus (4 µg/ml). The
diameter of zone of inhibition obtained from agar disk diffusion
experiment was presented in Table 1 and S. epidermis recorded
significant diameter of zone of inhibition (33 mm) and is
shown in Figure 3. The activity of Pseudopyronine B against
S. epidermis was superior to ciprofloxacin, standard antimicrobial
agent (Table 1).
Antifungal Activity of Pseudopyronine B
Antifungal property of Pseudopyronine B against 11 fungi
and the MIC values are shown in Table 2. Pseudopyronine B
documented good antifungal property especially against plant
pathogenic fungi. Pseudopyronine B displayed best MIC value
against P. expansum (4 µg/ml), followed by F. oxysporum and
R. solani (16 µg/ml). In agar disk diffusion assay P. expansum
recorded significant activity (34 mm; Table 2; Figure 3).
Anticancer Activity
Pseudopyronine B Recorded Significant
Anti-proliferative Activity as Evidenced by MTT Assay
Anti-proliferative activity of Pseudopyronine B was assessed
on non-small cell lung cancer (A549), mouse melanoma cell
(B16F10) and liver cancer cell (HepG2) lines. MTT assay
was used to evaluate the cell viability after Pseudopyronine
B treatment. From the MTT experiment it is clearly evident
that the Pseudopyronine B recorded both dose- and time-
dependent inhibition in the growth of test cancer cell lines,
when treated with 100, 50, 10, 5, 1, and 0.5 µg/ml (Figure 4A).
Out of three cell lines tested, A549 and B16F10 cells recorded
best activity. A549 and B16F10 cells turned out to be the
most sensitive cell lines and were selected for further apoptotic
studies.
Apoptotic Induction Assays
Pseudopyronine B Induces Apoptosis in A549 and
B16F10 as Evidenced by Acridine Orange-Ethidium
Bromide and Hoechst 33342 Staining
The cultured A549 and B16F10 cells were examined for their
morphology features after treatment with Pseudopyronine B.
It was observed that the Pseudopyronine B is inducing
characteristic apoptosis features changes such as nuclear
condensation, membrane blebbing and formation of apoptotic
bodies, when compared to untreated control as evaluated by
phase contrast microscope. Moreover, there was a significant
reduction in the number of A549 and B16F10 cells after
Pseudopyronine B treatment (Figure 4B). Acridine orange-
ethidium bromide staining was done to confirm the nuclear
membrane damage, a characteristic feature of apoptosis as
observed by yellow/orange coloration in the nuclei of A549 and
B16F10 cells treated with Pseudopyronine B (Figure 5). The
cells treated with the compound after 24, 48 and 72 h exhibited
time depend increase in AO-EB positivity, when compared to
untreated control (Figure 5).
The Hoechst 33342 staining of A549 and B16F10 cells
recorded a very significant increase in the number of cancer
cells showing nuclear condensation and fragmentation
after treatment with Pseudopyronine B when examined
through phase contrast microscope (Figure 6). Moreover,
cancer cells lost its normal structure after treatment with
Pseudopyronine B and presented an expansion of the
endoplasmic reticulum. Some very specific signs of early
stages of apoptosis (vacuolization in the cytoplasm, nucleus
shrinkage and fragmentation and chromatin densification) can
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FIGURE 2 | (A) Structure of Pseudopyronine B and (B) HR–MS spectra of Pseudopyronine B.
also be viewed in Pseudopyronine B treated cells through phase
contrast microscope (Figure 6).
Effect of Pseudopyronine B on Cell Cycle Analysis
Distribution of cells on the different phases of the cell cycle
was investigated by flow cytometry after treatment of A549 and
B16F10 cells with several concentrations of Pseudopyronine B
for 24, 48, and 72 h. In both A549 and B16F10 Pseudopyronine
B treated cells, G1 and G2/M phase were increased were as S
phases found to be decreased. In A549 cells at 48 h of incubation
control cells possess 68.96 ± 2.94% in G1 phase were as in
Pseudopyronine B treated cells have 76.36± 2.67%. Control cells
in G2/M phase possess 5.88± 0.84% were as in Pseudopyronine B
treated cells have 11.88 ± 1.04%. In B16F10 cells at 48 h of
incubation control cells possess 70.62± 3.56% and 72.79± 3.21%
for Pseudopyronine B treated cells. In G2/M phase control cells
possess 17.59 ± 1.59% and 21.12 ± 1.64% for Pseudopyronine B
treated cells suggesting that it can induce significant apoptosis in
A549 and B16F10 cells (Figure 7).
Pseudopyronine B Induces Apoptotic Events by
Altering Membrane Permeability as Evidenced by
Flow Cytometry
Annexin V-FITC staining, using flow cytometry was used
to detect the morphological changes that occur in the early
stages of apoptotic cells (Figure 8). After 48 h of treatment,
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TABLE 1 | Antibacterial activity of Pseudopyronine B.
Test bacteria Pseudopyronine B Ciprofloxacin
MIC
(µg/ml)
MBC
(µg/ml)
Zone of inhibition
(Diagram in mm)
MIC
(µg/ml)
MIC
(µg/ml)
Zone of inhibition
(Diagram in mm)
B. subtilis 64 125 20 ± 1 2 2 30 ± 1
B. cereus 16 32 23 ± 0 1 2 31 ± 1.52
S. aureus 4 4 31 ± 0.23 1 2 33 ± 1.14
S. epidermis 1 2 33 ± 0.56 2 4 30 ± 1.77
S. simulans 8 8 28 ± 1.72 4 4 29 ± 0.56
E. coli – – – 1 2 27 ± 0.77
P. mirabilis – – – 0.5 1 29 ± 0.56
P. vulgaris MTCC 1771 – – – 2 4 30 ± 1.15
V. cholerae – – – 2 4 31 ± 1.72
K. pneumonia 4 8 25 1 2 25 ± 1.15
P. aeruginosa – – – 2 4 27 ± 0
S. typhi 32 32 22 4 4 29 ± 1
–, recorded no activity.
Pseudopyronine B induced apoptosis on A549 [14.1 ± 1.34%
in control to 76.5 ± 2.97% in Pseudopyronine B treated
cells (P < 0.001)] and B16F10 [21.7 ± 1.68% in control to
64.7± 2.67% in Pseudopyronine B treated cells (P< 0.001)] cells.
Pseudopyronine B Induces Caspase 3 Activation in
Cells
Our next attempt was to examine the basic mechanism
behind the cytotoxic effect of Pseudopyronine B. For this,
we tested the activation of caspase 3 using a colorimetric
assay. Pseudopyronine B treated cells and control lysates were
prepared and incubated with Ac-DEVD-pNA caspase 3 specific
substrate with the reaction buffer and the caspase 3 pNA
release was measured using a spectrophotometer at 405 nm.
Significant enhancement in the caspase 3 activity was recorded
in Pseudopyronine B treated cells when compared with that
of control clearly indicating the involvement of caspase 3 in
Pseudopyronine B induced apoptotic cell death (Figure 9). The
results are given in Figure 9.
Evaluation of Immunomodulatory Properties of
Pseudopyronine B
Immunomodulatory activity of Pseudopyronine B was checked
by the proliferation of lymphocyte. The proliferation lymphocyte
was slightly enhanced in Pseudopyronine B treated cells when
compared to that of control cells (untreated). The proliferation
index of lymphocyte was detected to be 1.08 for 5 µg/ml of
Pseudopyronine B in the presence of PHA (Figure 10).
DISCUSSION
The enormous rise in the value of drug discovery and
development is a strong encouragement for many pharmaceutical
industries to contempt all but the most economically bioactive
FIGURE 3 | Antimicrobial activity of Pseudopyronine B.
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TABLE 2 | Antifungal activity of Pseudopyronine B.
Test bacteria Pseudopyronine B Amphotericin B
MIC
(µg/ml)
Zone of
inhibition
(Diagram in mm)
MIC
(µg/ml)
Zone of
inhibition
(Diagram in mm)
A. flavus 16 21 ± 0.52 4 23 ± 1.15
A. fumigatus 64 18 ± 0.77 2 27 ± 1.72
A. niger 32 21 ± 1.12 2 26 ± 0.56
A. tubingensis – – 4 30 ± 0.77
C. gloeosporioides – – 32 25 ± 1.12
F. oxysporum 16 25 ± 1.12 125 26 ± 2.21
P. expansum 4 34 ± 0.52 64 23 ± 2.27
R. solani 16 24 ± 1 64 23 ± 072
T. rubrum – – 2 24 ± 0.56
–, recorded no activity.
lead molecules (Higginbotham et al., 2013). But, the decreasing
quantity of medicines reaching the market is putting strong
pressure on the pharmaceutical companies to research and
find alternative sources for novel lead molecules (Bennani,
2012). Natural molecules with diverse bioactivity have been
used since the beginning of various conventional medicines in
early years (Graca et al., 2013). These bioactive molecules are
present in all forms of life and are usually produced during the
secondary metabolism by almost all organisms. A wide variety
of structurally interesting and bioactive secondary metabolites
produced by various microorganisms including bacteria, fungi,
actinomycetes, etc. have been reported worldwide and many
of them are taken by the several pharmaceutical companies as
lead drug molecules especially antibiotics (Gao et al., 2012).
Several microbes especially from terrestrial soils have an inborn
capability of producing many novel natural molecules with
various biological properties and this represent rich source of
biologically active compounds which may play very important
role in drug discovery process for pharma industry (Bode et al.,
2002). In the present study, a bacterial strain, named as TR, was
isolated from soil during a screening for microbes with potent
antimicrobial property. The microbial strain used in the present
study was identified as a P. mosselii strain based 16 S rDNA
sequencing and BLAST analyses.
There are many literature reports on the production of
compounds with antimicrobial properties by Pseudomonas spp.
Some of these antimicrobial compounds have been identified
FIGURE 4 | (A) Cytotoxicity profile of Pseudopyronine B on A549 and B16F10 cells measured by MTT assay. (B) Phase contract images of A549 and B16F10 cells
treated with Pseudopyronine B. The experiments where performed in three replication and results were expressed as mean ± standard deviation.
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FIGURE 5 | Analysis of A549 and B16F10 cell lines to detect apoptosis by Acridine orange/ethidium bromide staining. In this method live cells were
detected as green color, whereas the apoptosis cells documented orange-red due to the co-staining of acridine orange with ethidium bromide stain due to the loss
of membrane integrity by the action of Pseudopyronine B.
chemically and the structure has been reported (Zhou et al.,
2012). Several fluorescent Pseudomonas spp. have currently
received world-wide interest due to the production of a
board range of bioactive compounds with antibiotics properties
such as phenazine-1-carboxylic acid, pyoluteorin, phenazine-1-
carboxamide, viscosinamide and tesin (Chin-A-Woeng et al.,
2003; Hu et al., 2005; Huang et al., 2009) and several
bioactive enzymes. In this study, P. mosselii exhibit remarkable
antimicrobial property especially against a broad range of
plant pathogenic fungi, Gram-positive and negative human
pathogenic bacteria. So far, many antibiotics have been isolated
and identified from Pseudomonas species, and most of them
were from P. aeruginosa, which is the most studied species of
Pseudomonas. P. mosselii is one of the Pseudomonas species that
has not been studied extensively. In the present study we have
isolated Pseudopyronines B from P. mosselii and the isolation of
Pseudopyronine B from P. mosselii is reported here for the first
time.
The isolation of Pseudopyronines A and B is previously
reported from marine sponge associated Pseudomonas species
collected from the Fiji islands (Singh et al., 2003, 2011; Kong et al.,
2005) and Pseudomonas sp. associated with entomopathogenic
nematode (Grundmann et al., 2012). These compounds showed
significant MICs against Gram-positive bacteria, including
S. aureus, B. subtilis, methicillin-resistant S. aureus and
Enterococcus faecium (MIC value: 2–4 µg/ml) and reasonable
activity against E. faecalis and S. pneumoniae (MIC value: 16–
64 µg/ml) with being the more active of the two compounds
(Giddens et al., 2008; Singh et al., 2011). Similar results were
observed in our study also (Table 1), where in our study also
Staphylococcus spp. recorded best activity. Antimycobacterial
activity of pseudopyronines against M. tuberculosis H37Rv is
also well-reported in the literature (Giddens et al., 2008).
Pseudopyronines are powerful and comparatively selective
parasitic protozoa (Leishmania donovani) inhibitors (Blunt et al.,
2010). These reports clearly portrait the role of Pseudopyronines
in modern drug discovery process. The antifungal activity of
Pseudopyronines especially Pseudopyronine B is not reported in
literature. In the present manuscript the antifungal activity of
Pseudopyronine B especially against plant pathogenic fungi is
reported for the first time.
Bioactive compounds especially from natural have played
a significant role over several years in the growth of various
anticancer drugs. Many natural compounds and their derivatives
have been successfully categorized according to the standard
collection of several cancer drugs, such as paclitaxel, vinblastine,
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FIGURE 6 | Hoechst staining of A549 and B16F10 cells. Treatment with Pseudopyronine B resulted in apoptotic death.
FIGURE 7 | Effect of Pseudopyronine B against A549 and B16F10 on cell cycle. The experiments where performed in three replication and results in bar
diagram were expressed as mean ± standard deviation.
and vincristine (Zhong et al., 2012). Newman et al. (2003)
reported that more than 50% of the novel compounds approved
between 1982 and 2002 were derived directly or indirectly
from natural compounds. This clearly indicated that natural
compound play a profound role in the development of various
anticancer drugs. Even though cancer is the leading cause
of mortality worldwide and most of the chemotherapeutic
compounds already in clinic have been reported to exhibit severe
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FIGURE 8 | Pseudopyronine B induce phosphatidylserine exposure in
A549 and B16F10 cells. The cells were stained with annexin V-FITC and
propidium iodide. Analyses were performed by flow cytometry. Each data
represents mean ± SD from three independent experiments.
toxicity to normal cells, accompanied by other unwanted side
effects to our body. Moreover, most of these compound are
highly expensive, mutagenic, and carcinogenic (Cao et al., 2010).
Therefore, it is very important to find out low toxic anti-cancer
FIGURE 10 | In vitro lymphocyte proliferative activity of
Pseudopyronine B after 72 h of incubation period.
agents from natural sources. In this study, Pseudopyronine B was
isolated from natural source and was tested for its cytotoxicity
effect on A549, B16F10, and HepG2 cancer cell lines. We showed
that Pseudopyronine B effectively inhibited cell growth of A549
and B16F10. When compared to that of A549 and B16F10 cells,
Pseudopyronine B treated HepG2 cells recorded less activity.
Alterations in the apoptosis and its related signaling pathways
have a vital role in the development of tumor (Cao et al., 2010).
Pseudopyronine B treated A549a and B16F10 cells exhibited
typical morphological features of apoptosis including membrane
flip-flop, cell shrinkage, higher uptake of stain with apoptotic
markers and finally end up in severe DNA damage. The faults in
apoptosis pathway are supposed to be one of the important causes
FIGURE 9 | Effect of Pseudopyronine B on the release of caspase 3 in A549 and B16F10 cells. The experiments where performed in three replication and
results were expressed as mean ± standard deviation.
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of human cancer (Thompson, 1995). Thus, a compound which
induces apoptosis in cancer cells are one of the most efficient
approaches in treating cancer (Lowe and Lin, 2000).
The exact mode of action of Pseudopyronine B remains
unclear. Using acridine orange-ethidium bromide and Hoechst
staining assay, we observed that Pseudopyronine B induced
apoptosis and DNA damage in A549 and B16F10 cell lines.
Interesting in all most all cases, cellular DNA is the major
goal of many chemotherapeutic drug molecules, which directly
or indirectly attach to DNA. These drugs also obstruct DNA
metabolism and inhibit the action of DNA polymerases and/or
topoisomerases, which intern inhibit cell replication. Usually
apoptosis occurs, following cellular DNA damage. Cysteine-
containing aspartate-specific proteases (caspases) in the cells play
a very important role in the activation of various apoptotic
signaling pathways. So far, 10 members have been identified
in humans. Caspase-8 and caspase-9 are two initiator caspases
which are capable of transducing apoptosis signals by direct
activation of downstream executioner caspase-3 (Chen et al.,
2003). Caspase-3, a protein on the common path of cell apoptosis,
is one of the most important members and the key executor of cell
apoptosis. Caspase-3 usually exists in the cytoplasm in the form
of an inactive zymogen. When activated by the many external
apoptosis signals, caspase-3 can induce the inactivation of many
key proteases in the cytoplasm, cell nucleus, and cytoskeleton,
and finally cause the apoptosis of cells. In the current study,
cleavage of caspase-3 and up regulation of its cleaved form
in A549 and B16F10 cells treated with Pseudopyronine B
revealed Pseudopyronine B-induced apoptosis occurred through
the caspase-3-dependent pathway.
Cellular apoptosis (programmed cell death) is a common
form of cell death induced by many anticancer compounds/drugs
(Vaux and Korsmeyer, 1999). Apoptosis cells are well-categorized
by various morphological defects, such as condensation of
chromatin, membrane flip-flop, and the formation of apoptotic
body. These changes in cancer cells were finally leads to DNA
fragmentation which was observed as a ladder on agar gel
electrophoresis (Desagher and Martinou, 2000; Nonpunya et al.,
2014). Apoptosis is mainly induced by a caspase cascade or
translocation of apoptosis inducing factors (Nonpunya et al.,
2014). There are two important pathways in the activation of
caspase, which are the cell surface death receptor (extrinsic
pathway) and mitochondrial initiator (intrinsic pathway).
Caspase-3 and caspase-7 is the “execute” caspase for the apoptotic
induction, while caspase-8 and caspase-9 are the critical caspases
and signify the activation of the extrinsic and intrinsic pathways,
respectively (McConkey, 1998; Law et al., 2014). The activation
of caspases plays a significant role during apoptotic cell death;
especially, the caspase 3 activation and activation of this caspase
is an important step in the apoptosis procedure (Elmore, 2007).
Interestingly Pseudopyronine B recorded enhanced activation of
caspase 3, which may play an important role in apoptosis in A549
and B16F10 cells.
CONCLUSION
Here, it is highly evident from the present findings that a
P. mosselii which produces a powerful bioactive substance
(Pseudopyronine B), active against bacteria especially Gram-
positive. The present study contributes to the quest for
novel antimicrobial compounds, a vital strategy in emerging
alternative therapies to treat many infections caused by
pathogenic microbes. Pseudopyronine B also recorded significant
antifungal activity against plant pathogenic fungi. Isolation of
Pseudopyronine B from P. mosselii and antifungal activity is
reported here for the first time. Although, the present study
delivers some valuable basic information about Pseudopyronine
B from P. mosselii and further detailed investigation are needed
to determine their potential for clinical applications.
In the present study, we confirmed that Pseudopyronine B
inhibiting cell growth in a dose- and time-dependent manner.
We also demonstrated that the cell death is due to apoptosis. To
our best knowledge, this is the first investigation reporting the
anticancer activity of Pseudopyronine B, which has the potential
to be evaluated as a novel anticancer drug. Further studies
are warranted to decipher the molecular mechanisms by which
Pseudopyronine B modulates programmed cell death in various
cancer cells. More over the results in the present study clearly
point out the potential therapeutic property of Pseudopyronine
B as an anticancer agent.
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